Close
FINDING CURES TOGETHER<sup>SM</sup>

Fifth AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic

Monday, Jan. 8 

Tuesday, Jan. 9

Wednesday, Jan. 10

Thursday, Jan. 11


Monday, Jan. 8 

Welcome Remarks and Opening Keynote Lectures  
6-8 p.m.

Welcome Remarks
Fred R. Hirsch, CEO, IASLC

Immunotherapy in lung cancer: The good, the bad, and the ugly
Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, New York

The role of aneuploidy during tumorigenesis
Teresa Davoli, Harvard Medical School, Boston, Massachusetts

Functional lung cancer genomics through in vivo genome editing    
Monte M. Winslow, Stanford University School of Medicine, Stanford, California


Opening Reception
8-10 p.m.


Tuesday, Jan. 9

Continental Breakfast and Networking Roundtables
7-8 a.m.


Plenary Session 1: Early Steps in Lung Oncogenesis 
8-10 a.m.

Elucidating lung stem cells and the initiation of lung cancer at single-cell resolution
Mark A. Krasnow, Stanford University, Stanford, California

Early steps in lung oncogenesis
Samuel Janes, University College London, London, United Kingdom

Molecular mechanisms of lung cancer development: between metabolic reprogramming and genomic instability in the field of cancerization
Pierre P. Massion, Vanderbilt University Medical Center, Nashville, Tennessee

Influence of cancer initiation on tumor progression in SCLC
Julien Sage, Stanford University School of Medicine, Stanford, California

Modeling Rb loss and pathway reactivation in lung adenocarcinoma*
David M. Feldser, University of Pennsylvania, Philadelphia, Pennsylvania


Break

10-10:30 a.m.


Plenary Session 2: Early Detection
10:30 a.m.-12:25 p.m.

Individualized risk-based lung cancer screening: The way forward
Christine D. Berg, National Cancer Institute, Bethesda, Maryland

Inflammation and immunity in pulmonary premalignancy
Steven M. Dubinett, David Geffen School of Medicine at UCLA, Los Angeles, California

Intercepting lung cancer via the airway transcriptome
Avrum E. Spira, Boston University School of Medicine, Boston, Massachusetts

Gene networks, airway smoke injury, and cancer risk
Bruce A.J. Ponder, Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom

Diagnostic and prognostic utility of urinary creatine riboside for early stage non-small cell lung cancer*
Takahiro Oike, National Cancer Institute, Besthesda, Maryland


Poster A Highlights Session

12:25-12:35 p.m.


Poster Session A / Lunch
12:40-2 p.m.

Plenary Session 3: Liquid Biopsies
2:30-3:45 p.m.

Early detection of molecular residual disease in localized lung cancer via circulating tumor DNA profiling
Maximilian Diehn, Stanford University, Stanford, California

Circulating tumor DNA in early-stage NSCLC: A lung TRACERx study
Christopher Abbosh, University College London Cancer Institute, London, United Kingdom

ctDNA assessment of resistance and heterogeneity in EGFR mutant lung cancers
Zofia Piotrowska, Partners Cancer Care/MGH Cancer Center, Boston, Massachusetts


Break

3:45-4 p.m.


Plenary Session 4: Heterogeneity and Evolution
4-6:15 p.m.

Liquid biopsies and lung cancer evolution
Trever G. Bivona, University of California San Francisco, San Francisco, California

Tracking Lung Cancer Evolution through therapy-(TRACERx): Immune evasion, progression and adaptation
Charles Swanton, The Francis Crick Institute and University College London Cancer Institute, London, United Kingdom

Evolution of acquired resistance in EGFR-mutant NSCLC
Aaron N. Hata, Massachusetts General Hospital, Charlestown, Massachusetts

Cell-of-origin footprints in lung cancer genomes and transcriptomes
Marcin Imielinski, Weill Cornell Medical College, New York, New York

Dissecting the playbook of cancer: Genomic analysis of 100,000 human tumors reveals elaborate patterns of activation of the RTK-RAS-MAPK pathway*
Gerard Manning, Genentech, South San Francisco, California

Decoding tumor microenvironment to enhance NSCLC targeted therapy*
Haichuan Hu, MGH Cancer Center/Harvard Medical School, Charlestown, Massachusetts


Evening on Own
6:15 p.m.-

Top of page


Wednesday, Jan. 10

Continental Breakfast
7-8 a.m.


Plenary Session 5: Immunotherapy: Biomarkers and Checkpoint Blockade in NSCLC
8-10 a.m.

Immunotherapy: Biomarkers and checkpoint blockade in NSCLC
David P. Carbone, Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Mechanisms of acquired resistance to immune checkpoint inhibitors in lung cancer
Katerina A. Politi, Yale University Cancer Center, New Haven, Connecticut

Immunotherapy for thoracic malignancies beyond NSCLC​
Solange Peters, Centre Cordonne D'Oncologie - CHUV, Lausanne, Switzerland

Safety and activity of the IL-15/sIL-15Rα complex ALT-803 in combination with the anti-PD1 mAb nivolumab in metastatic non-small cell lung cancer*
John Wrangle, Medical University of South Carolina, Charleston, South Carolina

Investigating ectopic lymphoid aggregates in a genetically engineered mouse model of lung adenocarcinoma*
Kelli Connolly, Yale University, New Haven, Connecticut

Role of the microbiota in inflammation and lung cancer*
Ana I. Robles, National Cancer Institute, Besthesda, Maryland


Break

10-10:30 a.m.


Plenary Session 6
: Vaccines, Cellular Therapy, Neoantigen Targeting
10:30 a.m.-11:20 a.m.

Allele-specific HLA loss and immune escape in lung cancer evolution
Rachel Rosenthal, University College London, London, United Kingdom

Are tumors predictable? Inherited immune variation constrains tumor evolution
Hannah K. Carter, University of California San Diego, San Diego, California


Special Lecture
11:30 a.m.-12 p.m.

Developing precision medicine–based new lung cancer therapeutics
John D. Minna, UT Southwestern Medical Center, Dallas, Texas


Lunch on Own

12 p.m.-1:30 p.m.


Plenary Session 7: Small Cell Lung Cancer
1:30-3:40 p.m.

Mechanisms of chemoresistance in SCLC
Charles M. Rudin, Memorial Sloan Kettering Cancer Center, New York, New York

MYC drives molecular and therapeutically distinct subtype of SCLC
Trudy G. Oliver, University of Utah Huntsman Cancer Institute, Salt Lake City, Utah

The genomic landscape of SCLC and other neuroendocrine lung tumors
Julie George, University of Cologne, Cologne, Germany

Circulating Tumor Cells: A liquid biopsy for SCLC with multiple applications
Caroline Dive, Cancer Research UK Manchester Institute, Manchester, UK

Functional characterization and evolutionary reconstruction of small cell lung cancer transformation of EGFR-mutant lung adenocarcinomas*
June-Koo Lee, Harvard Medical School, Boston, Massachusetts

Alterations in cell junctions and neuroendocrine differentiation are key early steps in Crebbp/Ep300 mutation-driven SCLC development*
Kwon-Sik Park, University of Virginia, Charlottesville, Virginia


Break

3:40-4 p.m.


Plenary Session 8: Imaging, Radiation Oncology, Radiomics
4-5:30 p.m.

ImmunoPET imaging of DLL3 in small cell lung cancer
John T. Poirier, Memorial Sloan Kettering Cancer Center, New York, New York

Radiation therapy in lung cancer: Recent trends and future directions
Daniel R. Gomez, The University of Texas MD Anderson Cancer Center, Houston, Texas

Multiscale modeling of lung cancer
Olivier Gevaert, Stanford University, Stanford, California

Multimodality imaging of human lung squamous cell carcinoma reveals unique metabolic dependencies that are effectively targeted with metabolic based therapies*
David B. Shackelford, UCLA David Geffen School of Medicine, Los Angeles, California


Poster Session B Highlights

5:30-5:40 p.m.


Poster Session B
/ Reception
5:40-7 p.m.


Evening on Own
7 p.m.-

Top of page


Thursday, Jan. 11

Continental Breakfast
7-8 a.m.


Plenary Session 9: Tumor Microenvironment
8-10 a.m.

Comprehensive enumeration of immune cells in the tumor microenvironment using multiplexed ion beam imaging​
Michael Angelo, Stanford University School of Medicine, Stanford, California

Targeting cellular heterogeneity in lung adenocarcinoma
Tuomas Tammela, Memorial Sloan Kettering Cancer Center, New York, New York

Immune contexture evolution during lung cancer carcinogenesis and its potential clinical implications
Jianjun Zhang, The University of Texas MD Anderson Cancer Center, Houston, Texas

Regulatory T cells, polymorphisms, and response to checkpoint blockade: From mechanisms to potential biomarkers
Sergio Quezada, University College London Cancer Institute, London, United Kingdom

Hyperspectral imaging tools capture the spatial organization of cell subsets within the tumour microenvironment*
Katey S.S. Enfield, British Columbia Cancer Research Center, Vancouver, BC, Canada

Break
10-10:15 a.m.


Plenary Session 10: Targeted Therapies

10:15 a.m.-12 p.m.

Precise inhibition of oncogenic BRAF activation​
Zhan Yao, Memorial Sloan Kettering Cancer Center, New York, New York

A combined protein-protein interaction and genetic interaction map defines new and critical Kras effectors in non-small cell lung cancer*
Peter K. Jackson, Stanford University School of Medicine, Stanford, California

Progress and unanswered questions in EGFR mutation–positive lung cancer
Lecia Sequist, Massachusetts General Hospital, Boston, Massachusetts

MET copy number gain is associated with gefitinib resistance in leptomeningeal carcinomatosis of EGFR-mutant lung cancer*
Shigeki Nanjo, University of California San Francisco, San Francisco, California

The art in the science of ALK positive lung cancer management
Tony S.K. Mok, Chinese University of Hong Kong, Shatin, Hong Kong​


Departure

12 p.m.


*Short talk from proffered abstract


Top of page